ClinicalTrials.gg
Active, not recruitingNCT06459700ProOA23Updated Sep 8, 2026

Effect of Probiotic Supplements on Osteoarthritis Outcomes

An interventional study of Probiotic supplements and Placebo supplements in Knee Osteoarthritis, sponsored by Lund University. Active, not recruiting at 1 site in Sweden. Open to female participants aged 45 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Lund University · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
45 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Osteoarthritis, Knee with a site in Sweden — 12 open to participants now, 19 under way, none of them phase 3. Osteoarthritis, Knee · Sweden.

Planned enrollment
28th of 38
86 · median 175
Started
2024
with 4 others
No phase
23 of 54
7 open now
Primary completion
2027-04
later than 10 of 18 live
Registered
46th of 54
by date
Lead sponsor
8 of 54
Lund University

Among the 54 studies in Osteoarthritis, Knee with a site in Sweden, this one is the 28th largest by planned enrollment of the 38 interventional ones that give a count, is one of 5 that started in 2024, is one of 23 with no phase, reaches primary completion later than 10 of the 18 other live ones, and was the 46th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

12 of the 54 studies in Osteoarthritis, Knee with a site in Sweden are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 45 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Osteoarthritis, Knee with a site in Sweden, or all of them as a file.
02

Study summary

Dysbiosis of the gut microbiota is believed to contribute to the development and progression of osteoarthritis (OA), suggesting a role for probiotics in the treatment of OA. Animal studies have shown that certain probiotic strains decrease the inflammatory responses, pain sensitization and OA progression. There are, however, few clinical studies in humans to support this. In this double-blinded randomized controlled trial we will investigate the effect of 6-months probiotic supplements compared to placebo on OA related outcomes in females with diagnosed knee OA.

Read the detailed description

Aim:

To investigate the effect of 6-months probiotic supplements compared to placebo on OA related outcomes in females with diagnosed knee OA.

Design: Double-blinded randomized placebo controlled trial

Study arms: One treatment arm will receive probiotic supplement in opaque white capsules and the other treatment arm will receive identical opaque placebo capsules. The placebo product will contain maize starch powder. Study participants will take one capsule daily for six months.

Statistical analysis Main outcome: The independent T-test will be used to evaluate group differences in change in KOOS-12 scores between baseline and 6-months follow-up, given that all assumptions for parametric tests are satisfied. If assumptions are not met or if there are differences in baseline characteristics due to imbalanced randomization the Mann-Whitney U-test or regression analysis will be used as appropriate.

Secondary and explorative outcomes: The independent T-test (continuous, normal distributed data), the Mann-Whitney U-test (ordinal, non-normally distributed data) and cross-tabulations with Chi2 test (nominal data) will be used to evaluate differences in secondary and explorative outcomes between the two groups.

Estimated enrollment: 86 participants. Based on the ability to detect a 10-point difference in KOOS-12 with 80% power and α 0.05, 70 participants (35 per arm) will be needed. With an approximate drop-out rate of 20% from baseline to follow-up, 86 participants will be recruited.

Investigators: Eva Ageberg, PT, PhD, Professor in physical therapy, Lund University, Sweden (Principal investigator), Anna Cronström, physical therapist, PhD, Lund University, Sweden and Jessica Neilands, PhD, Associate Professor, Science manager, Probi AB, Lund, Sweden.

03

Conditions studied

  • Knee Osteoarthritis
04

Who can participate

Ages eligible
45 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Females aged 45-70 years
  2. Clinical diagnosis of knee OA
  3. Mild to moderate knee joint pain (Visual Analog Scale (VAS) 3-7)) during the last 3 months
  4. Able to perform walking and stair tests
  5. No use of other supplements/food products containing probiotics and/or supplements targeting OA symptoms (e.g., glucosamine, turmeric)
  6. Able to write and understand Swedish.

Exclusion criteria

Exclusion Criteria:

  1. Rheumatoid arthritis or other active generalised inflammatory comorbidities affecting the gastrointestinal tract (IBD, celiac disease)
  2. Performed a total knee replacement on the affected knee or on waiting list for joint replacement
  3. Other concomitant injuries or surgeries overriding the OA knee symptoms
  4. Other concomitant injuries or diseases where physical activity is a contra indication
  5. Malabsorption disorders, presence of renal and/or hepatic failure
  6. Use of with doses above 10 mg/day and/or Intra-articular injections during the previous 6 months
  7. Heavy use of alcohol (>10 standard units a week), or recreational drug use
  8. ≥30 Kg/m2
  9. Antibiotic treatment during the previous 2 months
  10. clinical depression diagnosis
  11. Pregnancy/breast feeding
  12. Smoking or other nicotine containing products during the previous 6months
  13. Performed a gastric bypass
  14. treatment or impaired immune system
  15. Chronic or acute diarrhoea
  16. Blood/plasma donation/transfusion during the 3months or during the study
  17. Non-controlled diabetes
  18. Allergy with regards to any of the study product ingredients.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
86 participants (estimated)

Study arms

  • Active comparator
    Probiotic

    One arm will receive probiotic supplement in opaque white capsules, 1 each day for six months

    Dietary Supplement: Probiotic supplements

  • Placebo comparator
    Placebo

    One arm will receive identical opaque placebo capsules containing maize starch powder (placebo), 1 each day for six months

    Dietary Supplement: Placebo supplements

Interventions

  • Dietary supplementProbiotic supplements

    See arm/group description

  • Dietary supplementPlacebo supplements

    See arm/group description

06

What researchers measure

Primary outcomes

  1. Knee injury and Osteoarthritis Outcome Score (KOOS)-12

    Change in the KOOS-12 (total score) from baseline to 6 months in the probiotic group compared with the placebo group. The KOOS-12 is scored from 1-100 (worst-best) scale.

    Time frame: 6 months

Secondary outcomes

  1. Knee injury and Osteoarthritis Outcome Score (separate subscale score)

    Comparison of the probiotic group with the placebo group in terms of changes from baseline to 3-month and 6-month follow-up in Scores on the separate subscales (pain, symptoms, activity of daily living, sport/recreation and knee-related quality of life) from the full KOOS questionnaire. The KOOS is scored from 1-100 (worst-best) scale.

    Time frame: 3 to 6 months

  2. Visual Analogue Scale (VAS)

    Comparison of the probiotic group with the placebo group in terms of changes from baseline to 3-month and 6-month follow-up in VAS scores (pain severity), assessed on an ordinal scale from 0 to 10 where 0 indicates no pain and 10 worst possible pain the last week

    Time frame: 3 to 6 months

  3. Work Productivity and Activity Impairment questionnaire (WPAI)

    Comparison of the probiotic group with the placebo group in terms of changes from baseline to 3-month and 6-month follow-up in WPAI. The WPAI questionnaire includes 6 questions regarding employee's absenteeism, reduced job performance, work productivity loss, and activity impairment. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes.

    Time frame: 3 to 6 months

  4. Patient Acceptable Symptom State (PASS)

    Comparison of the probiotic group with the placebo group in terms of changes from baseline to 3-month and 6-month follow-up in PASS. The PASS involves a question regarding if the patient is satisfied with their current knee function with to response options (yes/no)

    Time frame: 3 to 6 months

  5. Pain-relieving medication intake

    Comparison of the probiotic group with the placebo group in terms of changes from baseline to 3-month and 6-month follow-up in pain-relieving medication intake. Here the patients reports the type and dosage of any medication

    Time frame: 3 to 6 months

  6. Wish for surgery

    Comparison of the probiotic group with the placebo group in terms of changes from baseline to 3-month and 6-month follow-up in wish for surgery. The patients are asked if they wish to undergo surgery due to their knee problems (yes/no).

    Time frame: 3 to 6 months

  7. 40m fast paced walk test

    Comparison of the probiotic group with the placebo group in terms of changes from baseline and 6-month follow-up in 40m fast paced walk test, assessed as time taken to walk 4x10 meter as fast as possible

    Time frame: 6 months

  8. 30 seconds sit to stand test

    Comparison of the probiotic group with the placebo group in terms of changes from baseline and 6-month follow-up in the 30 seconds sit to stand test, assessed by the number of repetitions of sitting to standing from a chair during a period of 30 second.

    Time frame: 6 months

  9. Stair climb test

    Comparison of the probiotic group with the placebo group in terms of changes from baseline and 6-month follow-up in the stair climb test, assessed as time taken to ascend and descend a flight of 5 stairs.

    Time frame: 6 months

  10. 3 minute walk test

    Comparison of the probiotic group with the placebo group in terms of changes from baseline and 6-month follow-up in the 3 minute walk test, assessed as distance walked during 3 minutes on a treadmill.

    Time frame: 6 months

  11. Molecular biomarkers for cartilage degeneration and inflammation.

    Comparison of the probiotic group with the placebo group in terms of changes from baseline and 6-month follow-up in molecular biomarkers for cartilage degeneration and inflammation.

    Time frame: 6 months

Other outcomes

  1. Kinematics assessed with 3D motion analysis

    Comparison of the probiotic group with the placebo group in terms of changes from baseline and 6-month follow-up in Kinematics (joint angles in degrees) during the functional tasks

    Time frame: 6 months

  2. Kinetics assessed with 3D motion analysis and force plates

    Comparison of the probiotic group with the placebo group in terms of changes from baseline and 6-month follow-up in kinetics (joint moments (newton meter)) during the functional tasks.

    Time frame: 6 months

  3. Intestinal barrier integrity

    Comparison of the probiotic group with the placebo group in terms of changes from baseline and 6-month follow-up a molecular biomarker for intestinal barrier integrity (Zonulin)

    Time frame: 6 months

07

Study locations

1 site
  • MoReLab, Lund University
    Lund, 22100, Sweden
08

References and documents

Individual participant data

Plan to share: Yes — Plan description: De-identified IPD for primary and secondary outcomes will be made available upon reasonable request.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Statistical analysis plan will be published in a study protocol before completion of the analysis.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Apr 2027, 33 months after the start.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 33 months is above that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2024
First posted
Jun 14, 2024
StartActual
Jul 1, 2024
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2027
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06459700
Lead sponsor
Lund University
Collaborators
Probi AB
Responsible party
Sponsor
First posted
Jun 14, 2024
Start date
Jul 1, 2024
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Sep 8, 2026

Study contacts

Eva Ageberg
principal investigator · Lund University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion